Is Biomagnetics Diagnos Stock a Good Investment?
Biomagnetics Diagnos Investment Advice | BMGP |
- Examine Biomagnetics Diagnos' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Biomagnetics Diagnos' leadership team and their track record. Good management can help Biomagnetics Diagnos navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Diagnostics & Research space and any emerging trends that could impact Biomagnetics Diagnos' business and its evolving consumer preferences.
- Compare Biomagnetics Diagnos' performance and market position to its competitors. Analyze how Biomagnetics Diagnos is positioned in terms of product offerings, innovation, and market share.
- Check if Biomagnetics Diagnos pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Biomagnetics Diagnos' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Biomagnetics Diagnos stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Biomagnetics Diagnos is a good investment.
Not Rated
Examine Biomagnetics Diagnos Stock
Researching Biomagnetics Diagnos' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.01. Biomagnetics Diagnos had not issued any dividends in recent years. The entity had 1:250 split on the 28th of March 2006.
To determine if Biomagnetics Diagnos is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Biomagnetics Diagnos' research are outlined below:
| Biomagnetics Diagnos is way too risky over 90 days horizon | |
| Biomagnetics Diagnos has some characteristics of a very speculative penny stock | |
| Biomagnetics Diagnos appears to be risky and price may revert if volatility continues | |
| Biomagnetics Diagnos has high likelihood to experience some financial distress in the next 2 years | |
| Biomagnetics Diagnos currently holds 121.51 K in liabilities with Debt to Equity (D/E) ratio of 0.24, which may suggest the company is not taking enough advantage from borrowing. Biomagnetics Diagnos has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Biomagnetics Diagnos' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (518.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Biomagnetics Diagnos currently holds about 2.6 K in cash with (196.51 K) of positive cash flow from operations. | |
| Biomagnetics Diagnos has a frail financial position based on the latest SEC disclosures |
Biomagnetics Diagnos' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.72 M.Market Cap |
|
Biomagnetics Diagnos' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.45) | (0.43) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.61) | (0.58) |
Determining Biomagnetics Diagnos' profitability involves analyzing its financial statements and using various financial metrics to determine if Biomagnetics Diagnos is a good buy. For example, gross profit margin measures Biomagnetics Diagnos' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Biomagnetics Diagnos' profitability and make more informed investment decisions.
Evaluate Biomagnetics Diagnos' management efficiency
Biomagnetics Diagnos has return on total asset (ROA) of (0.3119) % which means that it has lost $0.3119 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6226) %, meaning that it created substantial loss on money invested by shareholders. Biomagnetics Diagnos' management efficiency ratios could be used to measure how well Biomagnetics Diagnos manages its routine affairs as well as how well it operates its assets and liabilities. As of 09/22/2025, Return On Tangible Assets is likely to drop to -0.42. In addition to that, Return On Capital Employed is likely to grow to -0.43. As of 09/22/2025, Total Current Liabilities is likely to grow to about 321.1 K. Also, Change To Liabilities is likely to grow to 5,012| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.01 | 0.01 | |
| Tangible Book Value Per Share | 0.01 | 0.01 | |
| Enterprise Value Over EBITDA | (1.46) | (1.38) | |
| Price Book Value Ratio | 0.01 | 0.01 | |
| Enterprise Value Multiple | (1.46) | (1.38) | |
| Price Fair Value | 0.01 | 0.01 | |
| Enterprise Value | 261.1 K | 274.2 K |
At Biomagnetics Diagnos, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta (0.32) |
Basic technical analysis of Biomagnetics Stock
Biomagnetics Diagnos technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Biomagnetics Diagnos' Outstanding Corporate Bonds
Biomagnetics Diagnos issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biomagnetics Diagnos uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biomagnetics bonds can be classified according to their maturity, which is the date when Biomagnetics Diagnos has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Biomagnetics Stock media impact
There is far too much social signal, news, headlines, and media speculation about Biomagnetics Diagnos that are available to investors today. This information is accessible both publicly - through Biomagnetics Diagnos' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Biomagnetics-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Biomagnetics Diagnos news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomagnetics Diagnos relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomagnetics Diagnos' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomagnetics Diagnos alpha.
Additional Tools for Biomagnetics Stock Analysis
When running Biomagnetics Diagnos' price analysis, check to measure Biomagnetics Diagnos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomagnetics Diagnos is operating at the current time. Most of Biomagnetics Diagnos' value examination focuses on studying past and present price action to predict the probability of Biomagnetics Diagnos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomagnetics Diagnos' price. Additionally, you may evaluate how the addition of Biomagnetics Diagnos to your portfolios can decrease your overall portfolio volatility.